Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioStem Technologies, Inc.BSEM · Entity 7054 | Director · Chief Operating Officer · 10% owner | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioStem Technologies, Inc.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,789,809 |
Reported balance
After 2026-10-07 transaction · row 1
1 source rowRow 1 · 2026-10-07 · Exercise / conversion · Acquired 250,000 · Balance 1,789,809 |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2032-10-24 | Direct | 2,000,000 |
Reported balance
After 2026-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-07 · Exercise / conversion · Disposed 250,000 · Balance 2,000,000 F4: These options are fully vested and exercisable. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2035-03-17 | Direct | 114,314 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 114,314 F5: These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2035-10-13 | Direct | 23,246 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 23,246 F6: These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-02-11 | Direct | 253,304 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 253,304 F7: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Series A-1 Convertible Preferred SharesSEC Table II · derivative / convertible security | Direct | 100 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 100 F1: The Series A-1 Convertible Preferred Shares are convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares. F2: The Series A-1 Convertible Preferred Shares have no expiration date. F3: Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 30,487 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 30,487 F8: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9: These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,442 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 57,442 F8: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F10: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 209,091 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 209,091 F8: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F11: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A-1 Convertible Preferred Shares are convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.
F2: The Series A-1 Convertible Preferred Shares have no expiration date.
F3: Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.
F4: These options are fully vested and exercisable.
F5: These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F6: These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F7: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F8: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F9: These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).
F10: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
F11: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionOptions (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001193125-26-419153 · ownership.xml · derivative · entry 3 SMITH-VAN VURST ANDREW · CIK 0002147206 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 250,000 shares Expires 2032-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| October 07, 2026 Filed Oct 9, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 250,000 | $2.00 | $500,000.00 |
DisclosureSEC source: 0001193125-26-419153 · ownership.xml · nonDerivative · entry 1 SMITH-VAN VURST ANDREW · CIK 0002147206 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,789,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 9,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394391 · ownership.xml · derivative · entry 8 SMITH-VAN VURST ANDREW · CIK 0002147206 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,442 Underlying: Common Stock · 9,574 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. F7 · derivative.expiration_date: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 9,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394391 · ownership.xml · nonDerivative · entry 2 SMITH-VAN VURST ANDREW · CIK 0002147206 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,539,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 7,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394391 · ownership.xml · derivative · entry 7 SMITH-VAN VURST ANDREW · CIK 0002147206 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,487 Underlying: Common Stock · 7,622 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024). F6 · derivative.expiration_date: These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024). Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 7,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394391 · ownership.xml · nonDerivative · entry 1 SMITH-VAN VURST ANDREW · CIK 0002147206 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,530,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.